Annovis Historical Income Statement

Stocks . USA . 
Stock . Annovis Bio
ANVS Stock  USD 6.71  0.17  2.60%   
Historical analysis of Annovis Bio income statement accounts such as Selling General Administrative of 3.3 M, Total Revenue of 0.0 or Gross Profit of 263.2 K can show how well Annovis Bio performed in making a profits. Evaluating Annovis Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Annovis Bio's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Annovis Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Annovis Bio is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Annovis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.

About Annovis Income Statement Analysis

Annovis Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Annovis Bio shareholders. The income statement also shows Annovis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Annovis Bio Income Statement Chart

At this time, Annovis Bio's Gross Profit is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 47.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 3.3 M in 2024.
Selling General Administrative  Other Operating Expenses  Research Development  Non Operating Income Net Other  
Add Fundamental

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Annovis Bio. It is also known as Annovis Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Annovis Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Annovis Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Annovis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.At this time, Annovis Bio's Gross Profit is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 47.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 3.3 M in 2024.
 2021 2022 2023 2024 (projected)
Research Development8.5M16.5M38.8M40.7M
Other Operating Expenses14.5M25.5M45.0M47.3M

Annovis Bio income statement Correlations

Discontinued Operations
Interest Expense
Selling General Administrative
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Income Tax Expense
Net Interest Income
Other Operating Expenses
Research Development
Ebitda
Depreciation And Amortization
Interest Income
Non Operating Income Net Other
Selling And Marketing Expenses
Discontinued Operations
-0.2-0.07-0.87-0.020.00.04-0.940.01-0.04-0.14-0.060.210.090.020.05-0.02-0.190.10.06-0.08
Interest Expense
-0.2-0.010.110.130.150.080.17-0.150.150.230.19-0.97-0.16-0.15-0.150.150.25-0.160.230.14
Selling General Administrative
-0.07-0.010.17-0.72-0.74-0.790.090.7-0.66-0.34-0.66-0.150.50.690.62-0.720.390.44-0.86-0.27
Gross Profit
-0.870.110.17-0.36-0.38-0.390.840.39-0.36-0.31-0.34-0.140.360.380.38-0.370.110.35-0.34-0.42
Operating Income
-0.020.13-0.72-0.361.00.97-0.07-1.01.00.890.99-0.04-0.95-1.0-0.991.0-0.05-0.930.90.83
Net Income From Continuing Ops
0.00.15-0.74-0.381.00.97-0.1-1.00.990.870.98-0.05-0.94-1.0-0.981.0-0.06-0.920.910.82
Ebit
0.040.08-0.79-0.390.970.97-0.13-0.970.960.810.940.02-0.88-0.97-0.940.97-0.29-0.850.950.76
Cost Of Revenue
-0.940.170.090.84-0.07-0.1-0.130.09-0.060.02-0.03-0.190.020.070.05-0.080.170.01-0.130.02
Total Operating Expenses
0.01-0.150.70.39-1.0-1.0-0.970.09-1.0-0.9-0.990.060.961.00.99-1.00.040.94-0.89-0.86
Income Before Tax
-0.040.15-0.66-0.361.00.990.96-0.06-1.00.930.99-0.07-0.98-1.0-1.01.0-0.01-0.960.860.87
Total Other Income Expense Net
-0.140.23-0.34-0.310.890.870.810.02-0.90.930.93-0.2-0.97-0.9-0.940.890.17-0.980.650.93
Net Income
-0.060.19-0.66-0.340.990.980.94-0.03-0.990.990.93-0.11-0.97-0.99-0.990.990.01-0.960.860.87
Income Tax Expense
0.21-0.97-0.15-0.14-0.04-0.050.02-0.190.06-0.07-0.2-0.110.090.060.08-0.06-0.310.11-0.12-0.11
Net Interest Income
0.09-0.160.50.36-0.95-0.94-0.880.020.96-0.98-0.97-0.970.090.960.99-0.95-0.141.0-0.74-0.93
Other Operating Expenses
0.02-0.150.690.38-1.0-1.0-0.970.071.0-1.0-0.9-0.990.060.960.99-1.00.040.94-0.89-0.86
Research Development
0.05-0.150.620.38-0.99-0.98-0.940.050.99-1.0-0.94-0.990.080.990.99-0.99-0.020.97-0.84-0.9
Ebitda
-0.020.15-0.72-0.371.01.00.97-0.08-1.01.00.890.99-0.06-0.95-1.0-0.99-0.05-0.930.90.83
Depreciation And Amortization
-0.190.250.390.11-0.05-0.06-0.290.170.04-0.010.170.01-0.31-0.140.04-0.02-0.05-0.2-0.340.14
Interest Income
0.1-0.160.440.35-0.93-0.92-0.850.010.94-0.96-0.98-0.960.111.00.940.97-0.93-0.2-0.7-0.94
Non Operating Income Net Other
0.060.23-0.86-0.340.90.910.95-0.13-0.890.860.650.86-0.12-0.74-0.89-0.840.9-0.34-0.70.61
Selling And Marketing Expenses
-0.080.14-0.27-0.420.830.820.760.02-0.860.870.930.87-0.11-0.93-0.86-0.90.830.14-0.940.61
Click cells to compare fundamentals

Annovis Bio Account Relationship Matchups

High Positive Relationship

Net Income From Continuing Ops
+ 1.0
Operating Income
Income Before Tax
+ 1.0
Operating Income
Ebitda
+ 1.0
Operating Income
Ebitda
+ 1.0
Net Income From Continuing Ops
Other Operating Expenses
+ 1.0
Total Operating Expenses
Ebitda
+ 1.0
Income Before Tax

High Negative Relationship

Ebitda
- 1.0
Other Operating Expenses
Research Development
- 1.0
Income Before Tax
Other Operating Expenses
- 1.0
Income Before Tax
Ebitda
- 1.0
Total Operating Expenses
Income Before Tax
- 1.0
Total Operating Expenses
Other Operating Expenses
- 1.0
Net Income From Continuing Ops

Annovis Bio income statement Accounts

201920202021202220232024 (projected)
Interest Expense40.9M47.2M13.3K182.7K210.1K199.6K
Selling General Administrative829.4K3.6M6.1M9.0M6.2M3.3M
Operating Income(1.6M)(6.6M)(14.5M)(25.5M)(45.0M)(42.8M)
Net Income From Continuing Ops(991.0K)(5.5M)(14.5M)(25.3M)(41.7M)(39.6M)
Ebit(1.6M)(12.1M)(29.0M)(25.5M)(45.0M)(42.8M)
Total Operating Expenses870.5K5.5M14.5M25.5M45.0M47.3M
Income Before Tax(991.0K)(5.5M)(14.5M)(25.3M)(56.2M)(53.4M)
Total Other Income Expense Net614.6K1.2M50.1K182.7K(11.2M)(10.6M)
Net Income Applicable To Common Shares(713.9K)(991.0K)(5.5M)(14.5M)(13.0M)(12.4M)
Net Income(296.8K)(4.3M)(14.4M)(25.1M)(56.2M)(53.4M)
Income Tax Expense(694.1K)(1.2M)(50.1K)(182.7K)(45.0K)(47.3K)
Net Interest Income(40.9K)47.2K13.3K182.7K675.9K709.7K
Other Operating Expenses870.5K5.5M14.5M25.5M45.0M47.3M
Research Development776.3K3.1M8.5M16.5M38.8M40.7M
Ebitda(791.0K)(5.5M)(14.5M)(25.5M)(45.0M)(42.8M)
Depreciation And Amortization814.6K6.6M14.5M25.5K1.00.95

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Annovis Stock Analysis

When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY